BACKGROUND: BRCA1/2 testing is one of the most well-established genetic tests to predict cancer risk. Guidelines are available to help clinicians determine who will benefit most from testing.
INTRODUCTION
Testing for hereditary breast/ovarian cancer (HBOC) susceptibility, commercially available since 1996, is one of the most wellestablished [1] [2] [3] and widely ordered genetic tests for cancer risk in the United States. Most health insurers reimburse at least partially for BRCA1/2 genetic testing for women with strong personal and/or family histories of breast or ovarian cancers. 4 Five to ten percent of breast cancers and 10% of ovarian cancers, or 18,000 new cases of breast cancer and 1,900 new cases of ovarian cancer per year, are believed to be hereditary. [5] [6] [7] BRCA1/ 2 mutations confer remarkable risks through age 75 of breast (35-84%) and ovarian (6-55%) cancers, 5, 8, 9 and prompt recommendations for aggressive surveillance and risk-reducing interventions 2,3 to lower cancer incidence or improve life expectancy. 10 A negative test result in a member of a family in which a disease-associated mutation has been identified should provide great reassurance. Currently, genetic testing is only recommended for women at increased risk for mutations. For example, 1 in 12 women with a strong family history of breast or ovarian cancer may carry a BRCA1/2 mutation. 11, 12 General population screening for BRCA1/2 mutations has not been recommended by cancer experts due to the low population prevalence of BRCA1/2 mutations (estimated to be only 1 in 300 to 500) and concerns regarding the potential physical and psychological consequences of difficult to interpret test results. [1] [2] [3] 8 A number of clinical practice guidelines have emerged providing specific criteria clinicians may use in determining whether referral for genetic counseling, identification and BRCA1/2 testing of affected family members, and/or BRCA1/ 2 testing for individual patients is appropriate. Three early sets of guidelines were developed as commercial and academic laboratories were making BRCA1/2 testing widely available. Two guidelines were developed by committees consisting primarily of oncologists, geneticists, and genetics counselors and disseminated to organizations of oncologists: the American Society of Clinical Oncologists published guidelines in 1996 (ASCO, 1996), 13 and the National Comprehensive Cancer
Network published guidelines in 1999 (NCCN, 1999 To our knowledge, there is no information in the published literature assessing the degree of compliance with these guidelines. In this study, we identify women in the 2000 and 2005 National Health Interview Survey (NHIS) Cancer Control Supplements at high risk for HBOC based on pre-2000 guideline criteria and develop national estimates of the proportion of women at high risk who have discussed the possibility of genetic testing with their doctor or another health-care professional, as suggested by these guidelines. We focus on women with a family rather than personal history of breast or ovarian cancer in order to concentrate on the implications of genetic risk assessment for cancer prevention in the primary care setting.
METHODS

Data
The NHIS is an in-person survey conducted annually by the National Center for Health Statistics to monitor the health of the US population. It uses a cross-sectional multistage area probability design to allow calculation of statistics representative of the US non-institutionalized population. In 2000 and 2005, 36,054 female respondents 18 and older participated in Cancer Control Supplements to the NHIS (combined final response rate of 71%). Respondents self-reported whether they or their first-degree relatives had ever been diagnosed with cancer, and if so, the type(s) and whether the cancer was diagnosed at age 50 or younger. Table 1 lists questions asked regarding awareness of and experience with genetic testing for cancer risk. Responses to these items are our main outcome measures.
Application of Guideline Criteria
We first used the 1996 ASCO, 1999 NYS/ACMG, and 1999 NCCN guidelines to categorize respondents as being at high risk (meeting at least one guideline criterion) or average risk (meeting no guideline criteria) for HBOC. These guidelines have explicit criteria, and all were available prior to the first year of our data, 2000 (Table 2 ). Family members' BRCA1/2 mutation status, HBOC-relevant ethnicity (e.g., Ashkenazi Jewish), breast cancer diagnoses in family members prior to age 45, diagnoses of multiple primary breast cancers (including bilateral cancer), and cancer diagnoses among second-and third-degree relatives are unavailable in the NHIS. Thus, our approach to identifying respondents at high risk of HBOCwomen meeting guideline criteria for potential counseling and testing-is based solely on the cancer histories of first-degree relatives, underestimating the prevalence of individuals who are candidates for testing in this population-based study.
Having assessed risk, we then determined whether our main outcomes varied by risk status.
Our second analysis assessed how well the above guidelines agreed with one another in determining high HBOC risk. 
Statistical Analysis
Bivariate analyses were used to track changes in respondents' awareness of and experience with genetic testing for cancer risk from 2000 to 2005, to compare the characteristics of women at high and average risk for HBOC, and to compare respondents' awareness of and experience with genetic testing for HBOC risk. Statistically significant differences were identified using Pearson's chi-squared statistics. Given that characteristics of women at high and average risk for HBOC did not change significantly from 2000 to 2005, our descriptive statistics are based on data pooled across the two survey years.
Poisson regression was used to calculate relative risks (RRs) 18 describing the differences in the main outcome measures detailed in Table 1 for women at high versus average risk of HBOC, controlling for survey year. We tested an interaction term to determine whether the association between risk status and outcomes changed from 2000 to 2005. Similar regressions were used to assess changes in the main outcome measures as a function of the number of guidelines for which a respondent met at least one criterion indicating high risk of HBOC. Agreement among the guidelines was assessed using the kappa statistic of interrater agreement.
All analyses were conducted using Intercooled Stata 9.2 for Windows (Stata Corporation, College Station, TX) taking account of NHIS design characteristics. 
RESULTS
Knowledge of and Experience with Genetic Testing
Of the 36,054 female respondents to the NHIS Cancer Control Supplements, 35,116 (97%) met our inclusion criterion of no personal history of breast or ovarian cancer. From 2000 to 2005, the fraction of these women who had heard of genetic testing for cancer risk declined three percentage points, from approximately 44% to 41% (p<0.001) ( Table 1) . Nevertheless, the proportion of women in our study population who reported having discussed the possibility of genetic testing with a health professional increased by a third, from 1.79% to 2.38% (p= 0.002), and the number advised by a health profession to get tested increased by 40%, from 0.62% to 0.87% (p=0.01) over that same time period. We did not have power to detect significant changes over time in genetic testing rates for breast/ovarian cancer.
Prevalence of Family History
Based on the history of breast or ovarian cancer among first degree relatives, high risk of HBOC was identified for 0.12% of respondents according to the 1996 ASCO guidelines, 0.92% of respondents according to the 1999 NCCN guidelines, and 0.35% of respondents according to the 1999 NYS/ACMG guidelines ( Table 2 ). The majority of these women met criteria based on having relatives diagnosed with breast cancer. Overall, 0.96% of respondents were deemed at high risk of HBOC according to at least one guideline: 0.56% met the criteria for one set of guidelines, 0.35% met the criteria of two sets of guidelines, and 0.04% met the criteria for all three guidelines.
Interguideline Agreement
The 
Characteristics of the Sample
Characteristics of our study population are summarized in Table 3 . Women meeting at least one criterion for high risk of HBOC according to any of the three pre-2000 guidelines tended to be older than average-risk women, as would be expected. High-risk women were less likely to self-identify as Hispanic and more likely to have had a clinical breast exam, a mammogram, or a diagnosis of cancer somewhere other than the breast or ovaries than average-risk women. Race, education, poverty status, having a usual source of care, and having had a visit to a health professional in the past year were not significantly associated with being at high risk for HBOC according to at least one guideline.
Women's Awareness of and Experience with Genetic Testing for Cancer Risk
Women's reported awareness of and experience with genetic testing was similar regardless of which guideline was used to identify them as being at high risk for HBOC, both in terms of the proportion of women responding "yes" on the main outcome measures and the relative difference between those deemed at high versus average risk of HBOC (Table 4) . Among women deemed at high risk of HBOC according to at least one guideline criterion, 54% had heard of genetic testing for cancer risk, just over 10% had discussed genetic testing for cancer risk with a health professional, fewer than 5% were advised by a health professional to be tested, and fewer than 2% actually underwent testing. Women at high risk of HBOC according to any guideline were 29% more likely to have heard of genetic testing for cancer risk than women at average risk of HBOC, controlling for survey year (RR 1.3, 95% CI 1.2-1.4, p<0.001). Women at high risk for HBOC were five times as likely to have discussed genetic testing for cancer risk with a health professional compared to women at average risk, controlling for survey year (RR 5.2, 95% CI 3.6-7.4, p<0.001). Women at high risk of HBOC were over six times more likely to have been advised by a health professional to be tested (RR 6.4, 95% CI 3.4-11.9, p< 0.001), and nearly seven times more likely to have been tested specifically for breast/ovarian cancer risk (RR 6.8, 95% CI 2.6-18.0, p< 0.001) than average-risk women, controlling for survey year. Based on statistical tests of the interaction between HBOC risk and year, there was no evidence that the relative difference in outcomes between those at high and average risk for HBOC changed between survey years, indicating similar changes over time for both high-and averagerisk women.
Awareness of genetic testing for cancer risk was similar whether criteria for 1, 2, or 3 guidelines were met (Table 5) . However, discussion of genetic testing for cancer risk with a health professional increased monotonically with increasing agreement among the guidelines. While only 8% of women meeting criteria for high risk of HBOC on just one set of guidelines discussed testing, more than 32% of women deemed high-risk by all three guidelines had such discussions. Advice to undergo genetic testing was also highest among women deemed high risk according to all three guidelines.
DISCUSSION
Using nationally representative survey data, our analysis indicates that only 10% of women nationally who met guideline criteria for consideration of genetic counseling for breast/ ovarian cancer risk report having discussed such a possibility with a health professional. Though 10% is low in absolute terms, it is reassuring to note that high risk women were five times as likely as average risk women to have had such a discussion and more than six times as likely to have been advised to seek testing. This suggests that while discussions of *High risk is defined as meeting at least one criterion from any one guideline in Table 2 † Average risk is defined as not meeting any criteria from any guideline in *High risk is defined as meeting at least one criterion from any one guideline in Table 2 † Average risk is defined as not meeting any criteria from any guideline on Table 2 ‡ RR = relative risk adjusted for survey year §
Statistic not available due to 0 cell count among high-risk women genetic assessment are being targeted correctly, many highrisk women are not being reached. Discussions of possible genetic testing are an important step in identifying an affected family member who may be a candidate for testing. Legitimate differences in preference may drive decisions to pursue genetic testing, but women at high risk of HBOC should at least discuss the possibility of testing with a health professional. Because BRCA1/2 testing is so well known, has well-accepted clinical utility, and has been around for so long, our findings provide nationally representative empirical evidence for the challenges involved in widespread dissemination of genetic medicine, particularly in primary care settings. The implications of low utilization of this effective cancer prevention strategy are not insignificant. Our analysis indicates that at least 0.96% of the population of women with no personal history of breast or ovarian cancer-or approximately 1,000,000 women-meet at least one guideline criterion suggesting they may be candidates for BRCA1/2 testing. Based on estimates of prevalence for deleterious BRCA1/2 mutations in this group (8.7%), 8 average penetrance (55% for breast cancer and 25% for ovarian cancer), 8 and our estimate that only 10.8% of high-risk women discuss the possibility of genetic testing with a health professional, we estimate that over 60,000 women may have missed an opportunity to reduce their cancer risk. Given that our analysis addressed the family history of first-degree relatives only and did not include other family history, ethnicity, or clinical criteria indicated in the guidelines, these estimates are very conservative. Other sources indicate that the prevalence of high risk for HBOC in this population may be as high as 2% 3 or even 4%. 19 The high agreement between risk defined collectively by the pre-2000 guidelines and current guidelines (2005 USPSTF and 2007 NCCN) provides confidence in our identification of high-risk women. Our results suggest that a substantial number of high-risk women are unaware that they carry a deleterious mutation and are thus unlikely to avail themselves of recommended prevention strategies, ranging from aggressive screening to prophylactic surgery, 2, 3, 20 which have been shown to be effective at reducing mortality among BRCA1/2 mutation carriers. 10 The low proportion of women at high risk for HBOC that report discussing genetic testing for cancer risk with their health professionals suggests a substantial disconnect between available clinical evidence and practice. Implementation of HBOC genetic screening guidelines has likely been hampered by several factors identified by physicians as common barriers to guideline compliance, including lack of awareness and familiarity with guidelines, lack of self-efficacy, and external barriers, 21, 22 as well as low levels of physician knowledge of clinical genetics and confidence counseling patients about genetic testing. [23] [24] [25] [26] Lack of awareness may stem from the fact that two out of three early guidelines were directed at oncologists rather than primary care providers (PCPs), those most likely to interact with women who have no personal history of breast or ovarian cancer. While the NYS/ ACMG guidelines were disseminated to PCPs, they were not distributed through maximally visible channels. The highprofile publication of the 2005 USPSTF guidelines, 3, 8, [27] [28] [29] [30] which was specifically aimed at PCPs, although available too late for physicians to apply in this population-was an important step forward, and future research should address the impact of these guidelines on primary care practice. The lack of consensus across guidelines may also be contributing to low rates of discussion. Our analyses indicate poor to fair agreement across the pre-2000 guidelines. However, women deemed at high risk of HBOC according to multiple guidelines were far more likely to have discussed genetic testing for cancer risk and been advised to seek such testing. This finding suggests that the intersection of agreement among these guidelines identifies a truly high-risk group and that the threshold for discussing/advising is high. It may also indicate that greater guideline concordance will lead to the identification of a higher proportion of high-risk women. Additional research is needed to assess whether recent increases in guideline concordance will improve identification of high-risk women in the future.
Although collection of family history data is the cornerstone of genetic risk assessment and is routinely collected at intake for new patients, it is rare for family history data to be recorded in adequate detail to implement practice guidelines. 24 The average PCP visit is 20 min in duration. 31 Physicians may be inadequately reimbursed to conduct a full family history. Acute concerns may also take precedence over prevention measures. 32 Federal plans to invest $19 billion in health information technology, including the mass implementation of electronic health records (EHRs), 33 may help PCPs collect and access family history data. Statutary requirements for certified EHRs and "meaningful use" will encourage the implementation of computerized decision support (CDS) tools linked to EHRs. CDS could be programmed to evaluate family history information, identify women at high risk for HBOC, and list actionable recommendations for follow-up, a particularly helpful feature for PCPs, the majority of whom are likely to see very few highrisk women. [34] [35] [36] [37] [38] However, this application of CDS has not yet been proven in clinical practice. Absent technological support [39] [40] [41] [42] [43] [44] [45] If these factors lead patients to withhold family history information from relevant health professionals (though not from survey interviewers), that would help explain the low rate of discussions we observe among our high-risk women. The study data were collected prior to the 2008 Genetic Information Nondiscrimination Act (GINA), during a time when virtually all protections from genetic discrimination existed in state law. Few states had laws comprehensive enough to allay the full spectrum of patient concerns. 46, 47 The extent to which GINA alleviates patient unease is an important area for future investigation. Our findings must be considered in light of certain limitations. As noted, we were only able to ascertain family history of breast and ovarian cancer for primary relatives. The exclusion of higher degree relatives reduces our ability to capture the full population of high-risk women. We were also unable to identify high-risk ethnic groups, for example, Ashkenazim; discussions of genetic counseling and testing are likely much more common in this group. However, less than 3% of the US population is of Ashkenazi Jewish ancestry, so the bias from misclassifying respondents' risk status as a result of missing ethnicity data is apt to be minimal. An additional limitation is the self-reported nature of NHIS data and the fact that the NHIS questions were not designed with this specific study in mind. We believe it unlikely that systematically inaccurate responses would induce a strong enough bias to explain the low rate of discussions we observe.
We found that through 2005, women meeting national guideline criteria for high HBOC risk rarely reported having had discussions of genetic counseling or testing with their health professionals, though they were much more likely to have such discussions than average risk women. Genetic testing for HBOC is one of the longest standing and best understood applications of clinical genetics. The failure to adequately capitalize on this beneficial genetic application places in stark relief the challenges associated with translating emerging genomics applications into broad clinical practice. Additional guideline dissemination efforts directed towards the primary care community, expanded use of CDS tools, or simplified guidelines are needed to assist PCPs and other providers in incorporating genetic strategies for risk assessment, prevention, and treatment into clinical practice. Addressing specific barriers to guideline implementation will help ensure that thousands of women get the information they need to address a potentially deadly threat to their health.
